All In Biotech

Drug Trial Radar · NCT06630286

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Bictegravir/Emtricitabine/Tenofovir Alafenamide in Virologically Suppressed People With HIV-1

A Phase 3, Randomized, Double-blind, Active-controlled Study to Evaluate a Switch to an Oral Weekly Islatravir/Lenacapavir Regimen in People With HIV-1 Who Are Virologically Suppressed on Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF)

Last checked: Nov 19, 2026Latest source record: Apr 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 609 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

609

Actual

Start

Oct 9, 2024

Primary completion

Apr 17, 2026

Study completion Aug 2030

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
Collaborators
Merck Sharp & Dohme LLC
First posted
Oct 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical study is to learn about the safety and efficacy of switching to once weekly tablet of islatravir/lenacapavir (ISL/LEN) regimen versus continuing standard treatment of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in people with human immunodeficiency virus (PWH) who are virologically suppressed (HIV-1 RNA levels \< 50 copies/mL) on B/F/TAF for ≥ 6 months prior to screening. The primary objective is to evaluate the efficacy of switching to oral weekly ISL/LEN tablet regimen versus continuing B/F/TAF in virologically suppressed PWH at Week 48.

Conditions

  • HIV-1-infection

Interventions

  • ISL/LENDrug

    Tablet administered orally

  • B/F/TAFDrug

    Tablet administered orally

  • PTM B/F/TAFDrug

    Tablet administered orally

  • PTM ISL/LENDrug

    Tablet administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants with HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Determined by the United States (US) Food and Drug Administration (FDA)-Defined Snapshot AlgorithmTime frame: Week 48

Locations

106 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama

  • Pueblo Family Physicians

    Phoenix, Arizona

  • Kaiser Permanente Southern California

    Los Angeles, California

  • Ruane Clinical Research Group, Inc

    Los Angeles, California

  • Mills Clinical Research

    Los Angeles, California

  • BIOS Clinical Research

    Palm Springs, California

  • Optimus Medical Group

    San Francisco, California

  • Vivent Health

    Denver, Colorado

  • University of Colorado- Anschutz Medical Campus - PPDS

    Denver, Colorado

  • Yale University

    New Haven, Connecticut

  • Georgetown University

    Washington D.C., District of Columbia

  • Whitman-Walker Health

    Washington D.C., District of Columbia

  • CAN Community Health

    Fort Lauderdale, Florida

  • Midway Immunology and Research Center

    Ft. Pierce, Florida

  • CAN Community Health

    Miami Gardens, Florida

  • Midland Research Group, Inc.

    Oakland Park, Florida

  • Orlando Immunology Center

    Orlando, Florida

  • AHF (AIDS Healthcare Foundation) - Pensacola Research

    Pensacola, Florida

  • CAN Community Health

    Sarasota, Florida

  • St. Josephs Comprehensive Research Institute

    Tampa, Florida

  • Emory University

    Atlanta, Georgia

  • Infectious Disease Specialists of Atlanta

    Decatur, Georgia

  • Mercer University

    Macon, Georgia

  • Chatham CARE Center

    Savannah, Georgia

  • Howard Brown Health

    Chicago, Illinois

  • Indiana University School of Medicine

    Indianapolis, Indiana

  • The Brigham and Women's Hospital, Inc.

    Boston, Massachusetts

  • Boston Medical Center

    Boston, Massachusetts

  • Community Research Initiative

    Boston, Massachusetts

  • Be Well Medical Center

    Berkley, Michigan

  • Trinity Health

    Grand Rapids, Michigan

  • KC CARE Health Center

    Kansas City, Missouri

  • ID CARE

    Hillsborough, New Jersey

  • Saint Michael's Medical Center

    Newark, New Jersey

  • South Jersey Infectious Disease

    Somers Point, New Jersey

  • AXCES Research Group - Albuquerque

    Santa Fe, New Mexico

  • Brooklyn Clinical Research Center

    Brooklyn, New York

  • New York Presbyterian Hospital

    Flushing, New York

  • Jacobi Medical Center

    The Bronx, New York

  • Montefiore Medical Center

    The Bronx, New York

Showing 40 of 106 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.